NCT03286868 Balancing Kinematically Aligned Total Knee Replacements During Total Primary Knee Arthroplasty Using Verasense
| NCT ID | NCT03286868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Scotia Health Authority |
| Condition | Osteo Arthritis Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2018-07-23 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2018-07-23 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Total Knee Replacement (TKR) is an operation to help with the pain and decreased function that happens with end stage arthritis of the knee. This operation has been shown to be very successful at relieving pain and improving patient mobility; however, some studies have shown that up to 20% of TKR recipients are not happy with their knee replacement. All of the reasons why some patients are not pleased with the outcome of surgery are not known, but one of the possible causes is the way the implants are placed, or aligned, during surgery. Most TKRs are aligned in a fashion that the bones in the leg are completely straight after surgery. This is known as mechanically aligning a TKR. A different alignment method known as kinematic alignment respects the natural bow legged or knock kneed alignment of the patient. It is hoped that kinematically aligning a knee replacement will improve how the knee feels to the patient and therefore improve their satisfaction. Another potential factor affecting the outcomes of TKR is obtaining optimal soft tissue balance. The challenge with balancing a TKR is that traditional operative techniques rely on subjective feel of the knee stability during surgery. The balance or tension in the knee can however be objectively measured using specialized intraoperative pressure sensing devices. The purpose of this study is to assess the impact of kinematically aligned TKR on the pressures measured by Verasense during total knee replacements. The study will also determine if differences in the pressure measured during TKR surgery impact patient outcomes after surgery.
Eligibility Criteria
Inclusion Criteria: * Symptomatic arthritis of the knee indicating primary total knee arthroplasty * Between the ages of 21 and 80 inclusive * Patients willing and able to comply with follow-up requirements and self-evaluations * Ability to give informed consent * Varus alignment Exclusion Criteria: * Patients less than 21 years of age, or 81 years of age and older * Unable to provide consent * BMI \>45 * Pregnancy * Patients with inflammatory arthritis, posttraumatic osteoarthritis, post high tibial osteotomy, or arthritis due to sepsis will be excluded. * Active or prior infection * Medical condition precluding major surgery * Severe osteoporosis or osteopenia * Neuromuscular impairment * Significant co-morbidity affecting ability to ambulate * Valgus alignment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03286868 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 80 Years, studying Osteo Arthritis Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03286868 currently recruiting?
Yes, NCT03286868 is actively recruiting participants. Contact the research team at elise.laende@nshealth.ca for enrollment information.
Where is the NCT03286868 trial being conducted?
This trial is being conducted at Halifax, Canada.
Who is sponsoring the NCT03286868 clinical trial?
NCT03286868 is sponsored by Nova Scotia Health Authority. The trial plans to enroll 60 participants.